Independent, Previous Senior Vice President and Head of Translational Sciences at Bayer Pharmaceuticals
Scientists have long been challenged by the complex process of drug discovery and development, with investments that often go unrewarded. However, with the advancement of experimental technology and computer hardware, artificial intelligence (AI) has emerged as a leading tool in analyzing abundant and high-dimensional data. It can be used in the discovery of drug targets, the design and development of new drugs, preclinical research, clinical trial design, and post-market surveillance to assist in the design of safe and effective drugs. While some limitations still remain in the AI-based drug R&D process, it is assumed that AI is an indispensable technology for the discovery of new drugs. In this context, it is remarkable that small companies with their power to innovate may play an important role in driving such technologies forward. One of those companies which I find particularly interesting is Kantify. Kantify is a European "TechBio" with the mission to improve human health with Artificial Intelligence. The company has developed a next generation small molecule discovery AI/ML platform, Zeptomics, which accelerates small molecule discovery and target identification with high performance and speed. Thanks to its breakthrough technology, the company is developing a growing pipeline of assets in oncology and rare diseases, including some small molecules and degraders for targets which were previously undrugged. It has established partnerships with research labs in Europe, the US and Singapore and has obtained extremely promising results on various targets.
At Kantify, we are committed to advancing pioneering science. In less than 30 seconds, this new video encapsulates our journey and our profound societal mission. Enjoy!
CEO at Kantify | Accelerating drug discovery in cancer and rare diseases, with Artificial Intelligence
9moThanks a lot for sharing this video and for raising awareness about the possible applications of AI in drug discovery and development! We could not be more excited of our first wave of results where our AI technology has discovered in a record time the first modulators to targets which were previously undrugged.